MDGL
Price
$440.89
Change
+$23.46 (+5.62%)
Updated
Sep 18, 04:59 PM (EDT)
Capitalization
9.52B
42 days until earnings call
VKTX
Price
$26.04
Change
+$2.95 (+12.78%)
Updated
Sep 18, 04:59 PM (EDT)
Capitalization
2.66B
34 days until earnings call
Interact to see
Advertisement

MDGL vs VKTX

Header iconMDGL vs VKTX Comparison
Open Charts MDGL vs VKTXBanner chart's image
Madrigal Pharmaceuticals
Price$440.89
Change+$23.46 (+5.62%)
Volume$3.27K
Capitalization9.52B
Viking Therapeutics
Price$26.04
Change+$2.95 (+12.78%)
Volume$178.19K
Capitalization2.66B
MDGL vs VKTX Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. VKTX commentary
Sep 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Hold and VKTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 18, 2025
Stock price -- (MDGL: $417.43 vs. VKTX: $23.09)
Brand notoriety: MDGL and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 70% vs. VKTX: 74%
Market capitalization -- MDGL: $9.52B vs. VKTX: $2.66B
MDGL [@Biotechnology] is valued at $9.52B. VKTX’s [@Biotechnology] market capitalization is $2.66B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.34B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileVKTX’s FA Score has 1 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • VKTX’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than VKTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 4 bullish, 4 bearish.
  • VKTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both MDGL and VKTX are a good buy in the short-term.

Price Growth

MDGL (@Biotechnology) experienced а -2.95% price change this week, while VKTX (@Biotechnology) price change was -10.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.96%. For the same industry, the average monthly price growth was +12.81%, and the average quarterly price growth was +39.84%.

Reported Earning Dates

MDGL is expected to report earnings on Oct 30, 2025.

VKTX is expected to report earnings on Oct 22, 2025.

Industries' Descriptions

@Biotechnology (+2.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($9.52B) has a higher market cap than VKTX($2.66B). MDGL YTD gains are higher at: 35.279 vs. VKTX (-42.619). VKTX has higher annual earnings (EBITDA): -212.42M vs. MDGL (-266.74M). VKTX (808M) and MDGL (797M) have equal amount of cash in the bank . VKTX has less debt than MDGL: VKTX (878K) vs MDGL (124M). MDGL has higher revenues than VKTX: MDGL (516M) vs VKTX (0).
MDGLVKTXMDGL / VKTX
Capitalization9.52B2.66B357%
EBITDA-266.74M-212.42M126%
Gain YTD35.279-42.619-83%
P/E RatioN/AN/A-
Revenue516M0-
Total Cash797M808M99%
Total Debt124M878K14,123%
FUNDAMENTALS RATINGS
MDGL vs VKTX: Fundamental Ratings
MDGL
VKTX
OUTLOOK RATING
1..100
7758
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
2982
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
3893
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (33) in the Biotechnology industry is in the same range as MDGL (65) in the Pharmaceuticals Other industry. This means that VKTX’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (29) in the Pharmaceuticals Other industry is somewhat better than the same rating for VKTX (82) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than VKTX’s over the last 12 months.

VKTX's SMR Rating (95) in the Biotechnology industry is in the same range as MDGL (97) in the Pharmaceuticals Other industry. This means that VKTX’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for VKTX (93) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than VKTX’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as VKTX (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLVKTX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 22 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LICQX18.14N/A
N/A
Lord Abbett International Equity R2
NSIDX15.15N/A
N/A
Northern Small Cap Index
ASMNX22.07N/A
N/A
AQR Small Cap Momentum Style N
SVFYX83.08N/A
N/A
Smead Value Y
GFAFX87.11-0.42
-0.48%
American Funds Growth Fund of Amer F1

VKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VKTX has been loosely correlated with NEVPF. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VKTX jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VKTX
1D Price
Change %
VKTX100%
-2.53%
NEVPF - VKTX
45%
Loosely correlated
N/A
SYRE - VKTX
41%
Loosely correlated
+1.82%
GPCR - VKTX
41%
Loosely correlated
-1.01%
LRMR - VKTX
38%
Loosely correlated
+2.00%
CRNX - VKTX
38%
Loosely correlated
+0.29%
More